|Publisher||: Academic Press|
|Release Date||: 2020-11-01|
|ISBN 10||: 0128167378|
|Pages||: 250 pages|
New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies provides general updated information on the resistance of various human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It discusses also the description of various targeted sensitizing agents that can reverse innate or acquired resistance when used in combination with various FDA-approved anti-CD20 antibodies. There have been a lot of reports in which the treatment with anti-CD20 antibodies for various lymphomas/leukemias has resulted in significant clinical responses; however, there have been also subsets of cancer patients who did not respond initially and several of the responding patients developed resistance to subsequent treatments with the same or different regimens. Therefore, the use of various immunosensitizing agents targeting resistant factors to reverse resistance has been considered and this book discusses each of them in depth, such as Bortexomib, Immunomodulation Agents, Obinutuzumab, Tumor Suppressors, and HDAC Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to anti-CD20 antibodies. Provides a general overview of various sensitizing agents that can work effectively when used in combination with anti-CD20 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to further antibody treatments Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field
This comprehensive and authoritative reference covers all aspects of the group of disorders collectively known as the lymphoid neoplasms. The reader is taken through a description of its normal cellular origins and the molecular genetic abnormalities that can lead to this group of conditions, a section of the book that has been considerably strengthened for this third edition, to the environmental factors that may be relevant to disease development, and, finally, to the pragmatic aspects of disease management. The authors synthesise for the reader apsects of current knowledge and likely future developments, and direct them to the appropriate resources should they wish to pursue particular avenues of scientific or literature research.
Perry’s The Chemotherapy Source Book, now in its fifth edition, provides information on the choice of chemotherapeutic agents, the use of combination chemotherapy, and the toxicity of individual drugs. Organized by site, this is the only book of its kind to focus strictly on the clinical practice of chemotherapy, and is meant to serve as a “one-stop shop” for information on choice of chemotherapeutic agents, treatment outlines, grading of side effects, and dose modification.
|Author||: Patrik Andersson,Christian Ostheimer|
|Publisher||: Frontiers Media SA|
|Release Date||: 2019-12-27|
|ISBN 10||: 2889631613|
|Pages||: 329 pages|
The immune system harbors great potential for controlling and eliminating tumors. Recent developments in the field of immuno-oncology has led to unprecedented clinical benefits for a broad spectrum of solid tumors. However, immunotherapy (IT) approaches currently have several limitations including (i) low response rate; (ii) development of resistance and (iii) causing severe immune-related adverse effects (IrAEs), which underline the importance of adequate patient selection. Importantly, IT holds promising synergistic potential when combined with standard-of-care chemotherapy, radiotherapy (RT) and anti-angiogenic therapy (AAT) as part of multi-modal oncologic treatment regimes. Published data suggest that there are potential synergy between RT and AAT, which ultimately could help potentiate the response to IT. However, the complex interactions between RT and IT and/or AAT remain poorly understood. Many research questions including optimal timing, scheduling and dosing, as well as patient selection and side effects of combined therapy approaches, remain to be addressed. This Research Topic aims to give a comprehensive overview of the current field with particular emphasis on the future outlook of RT and AAT as complementary approaches to improve IT in solid tumors.
Treatment of Cancer is a multi-author work and comprehensive guide on modern cancer treatment that aims to give clinician and student alike the framework for an integrated approach to patient care, including radiotherapy, chemotherapy, and surgery. Much information is presented in tables and charts for easy assimilation, and clear algorithms for patient pathways are included to make decisions straightforward while allowing for sound clinical judgement.
With thorough updates throughout, Clinical Radiation Oncology provides the most comprehensive, authoritative, and up-to-date information available for treating patients with cancer. From a multidisciplinary perspective, this new edition, edited by Drs. Leonard L. Gunderson and Joel E. Tepper, examines the therapeutic management of specific disease sites based on both single-modality and combined-modality approaches - providing you with the well-rounded, cutting-edge guidance you need to offer the most effective treatments. A consistent chapter format, full-color design, and access to the full text at www.expertconsult.com make reference fast and easy. It is an ideal resource for mastering the latest, most effective techniques and modalities! Deepen your knowledge with a comprehensive, clinical approach to the scientific foundations of radiation oncology and general oncology as well as state-of-the-art techniques and modalities. Implement a multidisciplinary, "team care" approach to providing intricate treatment plans for patients, often in conjunction with medical oncologists, and surgeons. Broaden your understanding of the basic biology of the disease processes. Examine the therapeutic management of specific disease sites based on single-modality and combined-modality approaches. Quickly and easily find critical information thanks to an easily accessible, full-color design with over 800 color figures that clearly depict treatment techniques. Get broad multimodality perspectives and unique insights from a diverse team of respected editors and contributors –many of whom are new to this edition – affiliated with institutions across North America and internationally Access the fully searchable text anywhere, anytime at www.expertconsult.com, along with references, additional images and tables, video clips and more! Stay current with comprehensive updates throughout that include a new chapter on survivorship issues, and additional video clips on treatments such as prostate and penile cancer brachytherapy. Improve outcomes by providing the most effective treatment for each patient with expanded coverage of new modalities and treatment regimens. Understand and comply with the latest staging guidelines.
|Author||: Abhishek D Garg,Patrizia Agostinis|
|Publisher||: Frontiers Media SA|
|Release Date||: 2016-04-29|
|ISBN 10||: 2889198383|
|Pages||: 329 pages|
Classically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated ‘danger signaling’ remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and ‘danger signaling’ has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of “immunogenic cell death” (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality.
Places the major advances which have occurred in the area of lymphoma into the context of daily clinical practice.
This is a comprehensive textbook of Hodgkin's and non-Hodgkin's lymphomas written by leaders in the field of childhood lymphomas. It includes clinical, pathologic and molecular biology of each subtype of lymphoma. The pathology chapters are comprehensive and include excellent photographs. The book is at the level of subspecialists in pediatric hematology and oncology, radiation oncology, pediatric surgery and hematopathology.
First Prize, Orthopaedics and Rheumatology, BMA Awards 2009 This state-of-the-art reference provides current insights into the etiology, diagnosis and management of rheumatoid arthritis. Leading international authorities in RA examine all of the latest scientific and clinical developments in understanding and managing this challenging disease, including new concepts in pathogenesis, epidemiology, risk factors, imaging, clinical outcomes and treatment. It’s the guidance you need to offer optimal care to your patients with rheumatoid arthritis. Presents the work of leading international experts in rheumatoid arthritis for guidance you can trust. Provides the very latest understanding of the pathogenesis of rheumatoid arthritis, including molecular pathways/mechanisms, and genetic and environmental factors that instigate and drive the disease. Includes comprehensive coverage of clinical features of rheumatoid arthritis including articular, peri-articular and extra-articular manifestations, comorbidities, and outcome measures—disease activity, joint assessment, imaging, and more—for expert diagnosis and monitoring of disease progression. Examines evidence-based treatment options—including traditional and biologic DMARDs and combination therapies—as well as promising therapies on the horizon, placing up-to-date guidance on disease modifying or disease controlling agents at your fingertips.
This book provides clinical practitioners and the research community with detailed information on the diagnosis, prognosis, and treatment of non-Hodgkin lymphoma, taking into account the significant growth in knowledge including multiple therapeutic advances that have been achieved over the past 5-10 years. The work is subdivided into epidemiology, pathogenesis, pathology, imaging, and therapy of the non-Hodgkin lymphomas. The full range of therapeutic options are examined according to the major subtypes of non-Hodgkin lymphoma and the most up-to-date information is provided on current standard treatment options, including stem cell transplantation as well as new cutting-edge therapeutics.
|Author||: Paul Silverman|
|Publisher||: Elsevier Health Sciences|
|Release Date||: 2012-04-27|
|ISBN 10||: 1455733334|
|Pages||: 768 pages|
Here’s the multidisciplinary guidance you need for optimal imaging of malignancies. Radiologists, surgeons, medical oncologists, and radiation oncologists offer state-of-the-art guidelines for diagnosis, staging, and surveillance, equipping all members of the cancer team to make the best possible use of today’s noninvasive diagnostic tools. Consult with the best. Dr. Paul M. Silverman and more than 100 other experts from MD Anderson Cancer Center provide you with today's most dependable answers on every aspect of the diagnosis, treatment, and management of the cancer patient. Recognize the characteristic presentation of each cancer via current imaging modalities and understand the clinical implications of your findings. Effectively use traditional imaging modalities such as Multidetector CT (MDCT), PET/CT, and MR in conjunction with the latest advances in molecular oncology and targeted therapies. Find information quickly and easily thanks to a consistent, highly templated format complete with "Key Point" summaries, algorithms, drawings, and full-color staging diagrams. Make confident decisions with guidance from comprehensive algorithms for better staging and imaging evaluation. Access the fully searchable text online, along with high-quality downloadable images for use in teaching and lecturing and online-only algorithms, at expertconsult.com.
Looks at the essential conepts in the science of pharmacology and its application to clinical practice.
"Summaries of papers" contained in the journal accompany each issue, 19--
|Author||: R. Cervera,Ricard Cervera|
|Release Date||: 2009-04-01|
|ISBN 10||: 9780080932347|
|Pages||: 266 pages|
Antiphospholipid syndrome is an autoimmune disease that causes abnormal blood clots. It is now recognized as a major cause of common conditions, including stroke, heart attack, miscarriage, epilepsy and memory loss and as such is gaining recognition in all branches of medicine, from obstetrics to cardiology, from psychiatry to orthopedics. This book provides an overview of our current understanding of this major disease. It includes the latest information on the new pathogenetic mechanisms involved as well as clinical manifestations in both “the thrombotic and “non-thrombotic manifestations of this important disease. * Comprehensive review of this major disease * Includes information on treatment options available
The most trusted and up-to-date pharmacology text in medicine -- completely redesigned to make the learning process even more interesting and efficient 5 Star Doody's Review! "This is the most widely used textbook for teaching pharmacology to health professionals. This 11th edition is far superior to any previous editions....The authors' goals are to provide a complete, authoritative, current, and readable textbook of pharmacology for students in health sciences. Testimony to their success is the widespread use of this work as required textbook for pharmacology courses around the world. This book is used extensively by thousands of medical, pharmacy, podiatry, nursing, and other health professions students to study pharmacology. Likewise, it remains a valuable resource for residents and practicing physicians....I continue to use this book as a required resource for all courses that I teach to medical, nursing, and allied health students. It is authoritative, readable, and supported by numerous learning tools."--Doody's Review Service Organized to reflect the syllabi in Pharmacology courses, Basic & Clinical Pharmacology covers all the important concepts students need to know about the science of pharmacology and its application to clinical practice. It is acknowledged worldwide as the field’s most current, authoritative, and comprehensive textbook. To be as clinically relevant as possible, the book features a strong focus on the choice and use of drugs in patients and the monitoring of their effects. Coverage that spans every important aspect of medical pharmacology: Basic Principles Autonomic Drugs Cardiovascular-Renal Drugs Drugs with Important Actions on Smooth Muscle Drugs that Act in the Central Nervous System Drugs Used to Treat Diseases of the Blood, Inflammation, and Gout Endocrine Drugs Chemotherapeutic Drugs Toxicology NEW to this edition: Full-color presentation, including 300+ illustrations Case studies introduce clinical problems in many chapters Drug summary tables for key information in comparative context Descriptions of important newly released drugs, including new immunopharmacologic agents Expanded coverage of general concepts relating to newly discovered receptors, receptor mechanisms, and drug transporters